--- title: "Eloxx Pharma | 10-Q: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/285302879.md" datetime: "2026-05-06T03:13:52.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285302879.md) - [en](https://longbridge.com/en/news/285302879.md) - [zh-HK](https://longbridge.com/zh-HK/news/285302879.md) --- # Eloxx Pharma | 10-Q: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -0.08. EBIT: As of FY2026 Q1, the actual value is USD -3.789 M. Eloxx Pharmaceuticals, Inc. operates as a single operating and reportable segment in life science, focusing on the development of clinical and preclinical product candidates to enhance ribosomal modulation . #### Financial Performance - **Net Loss**: The company reported a net loss of - $3.8 million for the three months ended March 31, 2026, compared to a net loss of - $1.7 million for the same period in 2025, representing a 120% increase in net loss . - **Operating Expenses**: - **Research and Development (R&D)**: R&D expenses increased by $1.1 million (225%) to $1.7 million for the three months ended March 31, 2026, from $0.5 million in the prior year . This increase was primarily due to a $0.6 million rise in clinical trial expenses, a $0.3 million increase in costs for subcontractors, advisors, and lab supplies for preclinical R&D, and a $0.2 million increase in salaries and personnel costs . Clinical and manufacturing expenses were $0.7 million in Q1 2026 compared to $38 thousand in Q1 2025 . Other research and development expenses were $1.0 million in Q1 2026 compared to $0.5 million in Q1 2025 . - **General and Administrative (G&A)**: G&A expenses rose by $1.4 million (200%) to $2.1 million for the three months ended March 31, 2026, from $0.7 million in the prior year . This increase was mainly driven by a $1.1 million rise in professional and consulting fees and a $0.3 million increase in facility and other overhead costs . - **Other (Income) Expense, Net**: The company reported other income, net, of less than - $0.1 million for the three months ended March 31, 2026, a change of - $0.5 million from other expense, net, of $0.5 million in the same period in 2025 . This was primarily due to a $0.4 million decrease in interest expense and a $0.1 million gain on extinguishment of accrued interest . #### Balance Sheet Highlights - **Cash and Cash Equivalents**: Cash and cash equivalents stood at $6.4 million as of March 31, 2026, up from $4.8 million as of December 31, 2025 . - **Total Current Assets**: Total current assets were $8.5 million as of March 31, 2026, compared to $5.3 million as of December 31, 2025 . - **Total Current Liabilities**: Total current liabilities were $16.1 million as of March 31, 2026, down from $17.2 million as of December 31, 2025 . - **Accumulated Deficit**: The accumulated deficit increased to - $304.3 million as of March 31, 2026, from - $300.6 million as of December 31, 2025 . - **Total Stockholders’ Deficit**: Total stockholders’ deficit was - $7.6 million as of March 31, 2026, an improvement from - $11.9 million as of December 31, 2025 . #### Cash Flow Activities - **Net Cash Used in Operating Activities**: Net cash used in operating activities was - $5.5 million for the three months ended March 31, 2026, a significant change from net cash provided by operating activities of $1.2 million for the same period in 2025 . - **Net Cash Provided by Financing Activities**: Net cash provided by financing activities was $7.0 million for the three months ended March 31, 2026, primarily from the sale of pre-funded warrants, compared to net cash used in financing activities of - $0.9 million for the same period in 2025 . #### Strategic Summary and Outlook Eloxx Pharmaceuticals, Inc. is focused on advancing exaluren for rare kidney diseases, with Phase 2b and Phase 2 clinical trials expected to initiate in the first half of 2026 and 2027, respectively, anticipating topline data by mid-2027 and mid-2028 . The company also licensed ZKN-013 to Almirall, S.A., making it eligible for up to approximately $470.0 million in milestone payments plus tiered royalties . However, Eloxx Pharmaceuticals, Inc.’s cash and cash equivalents of $6.4 million as of March 31, 2026, are not expected to be sufficient for its operations for the next twelve months, raising substantial doubt about its ability to continue as a going concern, and management plans to seek additional funding through debt, equity, or licensing arrangements . ### Related Stocks - [ELOX.US](https://longbridge.com/en/quote/ELOX.US.md) - [ELOXD.US](https://longbridge.com/en/quote/ELOXD.US.md) ## Related News & Research - [Eloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to Nasdaq | ELOX Stock News](https://longbridge.com/en/news/289119081.md) - [Gamehaus Holdings Inc. Announces Unaudited Financial Results for the Third Quarter of Fiscal 2026 Ended March 31, 2026 | GMHS Stock News](https://longbridge.com/en/news/289035965.md) - [Torrid Reports First Quarter 2026 Results and Fiscal 2026 Guidance | CURV Stock News](https://longbridge.com/en/news/288766232.md) - [Helus Pharma to Spotlight Late-Stage Mental Health Pipeline at H.C. Wainwright Neuro Conference](https://longbridge.com/en/news/289503646.md) - [Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 11, 2026, at 12:01 a.m., Eastern Time | SHPH Stock News](https://longbridge.com/en/news/289193564.md)